Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Structure Therapeutics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ACCG-2671 (ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST) DEMONSTRATED A ~6-DAY HALF-LIFE, NO SERIOUS ADVERSE EVENTS, AND EVIDENCE OF TARGET ENGAGEMENT INCLUDING UP TO 3.3% BODY WEIGHT LOSS IN PHASE 1/2A SAD CLINICAL TRIAL FIRST PARTICIPANTS DOSED WITH ACCG-2671 IN THE 12-WEEK MAD PORTION OF THE PHASE 1/2A CLINICAL TRIAL; TOPLINE DATA EXPECTED IN 1H 2027 ALENIGLIPRON (ORAL SMALL MOLECULE SELECTIVE GLP-1 RECEPTOR AGONIST) DEMONSTRATED UP TO 16.2% MEAN REDUCTION IN BODY WEIGHT AT 72 WEEKS WITH NO OBSERVED PLATEAU, AND IMPROVED TOLERABILITY WITH A 2.5 MG STARTING DOSE, INCLUDING LESS THAN 5% STUDY-DRUG DISCONTINUATION RATES DUE TO ADVERSE EVENTS IN THE ACCESS OLE CLINICAL TRIAL ACCOMPLISH-1 AND ACCOMPLISH-2 REGISTRATIONAL PHASE 3 CLINICAL TRIALS FOR ALENIGLIPRON ENROLLMENT ONGOING; TOPLINE DATA EXPECTED IN 2H 2028 COMPANY TO HOST CONFERENCE CALL TODAY AT 8:30 A.M. ET SAN FRANCISCO, SEPT.

STRUCTURE THERAPEUTICS REPORTS POSITIVE CLINICAL DATA ACROSSORAL SMALL MOLECULE AMYLIN AND GLP-1 PROGRAMS FOR CHRONIC WEIGHT MANAGEMENT

SAN FRANCISCO, SEPT. 03, 2026 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINICAL-STAGE GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL ORAL SMALL MOLECULE THERAPEUTICS FOR METABOLIC DISEASES, WITH A FOCUS ON OBESITY, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THREE UPCOMING HEALTHCARE CONFERENCES IN SEPTEMBER: 2026 CANTOR GLOBAL HEALTHCARE CONFERENCE DATE: THURSDAY, SEPTEMBER 10FORMAT: FIRESIDE CHAT AND 1X1 MEETINGSTIME: 3:55  4:25 PM EDTLOCATION: NEW YORK, NY MORGAN STANLEY 24 TH ANNUAL GLOBAL HEALTHCARE CONFERENCE DATE: WEDNESDAY, SEPTEMBER 16FORMAT: FIRESIDE CHAT AND 1X1 MEETINGSTIME: 10:45  11:20 AM EDTLOCATION: NEW YORK, NY BERNSTEIN'S 3RD ANNUAL HEALTHCARE FORUM DATE: WEDNESDAY, SEPTEMBER 23FORMAT: FIRESIDE CHAT AND 1X1 MEETINGSTIME: 3:00  3:40 PM EDTLOCATION: NEW YORK, NY THE LIVE AND ARCHIVED WEBCASTS WILL BE ACCESSIBLE FROM THE COMPANY'S WEBSITE ATHTTPS://IR.STRUCTURETX.COM/EVENTS-PRESENTATIONS/EVENTSAND REPLAYS WILL BE AVAILABLE FOR AT LEAST 90 DAYS.

STRUCTURE THERAPEUTICS TO PARTICIPATE IN UPCOMING HEALTHCARE INVESTOR CONFERENCES

PUBLICATION PRESENTED CONCURRENTLY WITH ORAL PRESENTATION AT AMERICAN DIABETES ASSOCIATION'S 86TH SCIENTIFIC SESSIONS FROM ACCESS DEVELOPMENT PROGRAM WITH ALENIGLIPRON, A ONCE-DAILY ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST

STRUCTURE THERAPEUTICS ANNOUNCES PUBLICATION IN NATURE MEDICINE HIGHLIGHTING PHASE 2B ACCESS PROGRAM OF ALENIGLIPRON FOR OBESITY

SAN FRANCISCO, MAY 26, 2026 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINICAL-STAGE GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL ORAL SMALL MOLECULE THERAPEUTICS FOR METABOLIC DISEASES, WITH A FOCUS ON OBESITY, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN TWO UPCOMING HEALTHCARE CONFERENCES IN JUNE:

STRUCTURE THERAPEUTICS ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

TOKYO, JAPAN AND CAMBRIDGE, UK, 11 MAY 202 6  AS ANNOUNCED ON 12 FEBRUARY 2026, NXERA PHARMA CO., LTD. (NXERA OR THE COMPANY) ENTERED INTO A LICENSE AGREEMENT WITH A NEWLY ESTABLISHED COMPANY (NEWCO) TO ADVANCE A SPECIFIC GPCR-TARGETED PROGRAM OWNED BY NXERA. NXERA TODAY ANNOUNCES THAT, IN CONNECTION WITH THE CLOSING OF A SERIES A FINANCING UNDERTAKEN BY NEWCO, NXERA AND A SYNDICATE OF LEADING HEALTHCARE AND LIFE SCIENCES-FOCUSED INVESTORS HAVE ENTERED INTO AN INVESTMENT AGREEMENT WITH NEWCO. NEWCO WILL ACCELERATE PRECLINICAL STUDIES OF A GPCR PROGRAM AGAINST A TARGET DISCOVERED USING NXERA'S NXWAVE TECHNOLOGY PLATFORM AND ADVANCE THE PROGRAM TOWARD GLOBAL CLINICAL TRIALS. BY PARTICIPATING IN THE SERIES A FINANCING, NXERA WILL CONTINUE ITS PARTNERSHIP WITH NEWCO TO MAXIMIZE IMPACT FOR PATIENTS AND THE VALUE OF THE PROGRAM FOR SHAREHOLDERS.

NXERA PHARMA ANNOUNCES PROGRESS OF OUT-LICENSING OF GPCR-TARGETED PROGRAM AND PARTICIPATION IN SERIES A FINANCING

REPORTED POSITIVE RESULTS FROM ALENIGLIPRON PHASE 2 ACCESS II STUDY WITH UP TO 16.3% BODY WEIGHT LOSS, DEMONSTRATING HIGHEST EFFICACY AMONG ORAL GLP-1RAS AT THE 44-WEEK TIME POINT AND POTENTIALLY COMPARABLE EFFICACY TO INJECTABLE GLP1-RAS DATA FROM ACCESS OLE EXPECTED IN Q3 2026; DATA FROM THE BODY COMPOSITION AND TYPE 2 DIABETES/OBESITY DATA EXPECTED IN Q4 2026 POSITIVE END-OF-PHASE 2 FEEDBACK RECEIVED FROM FDA; ALENIGLIPRON PHASE 3 INITIATION ON TRACK FOR Q3 2026 INITIAL DATA FROM PHASE 1 SINGLE ASCENDING DOSE (SAD) STUDY OF ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ACCG-2671 AND INITIATION OF MULTIPLE ASCENDING DOSE (MAD) STUDY EXPECTED IN Q3 2026; PHASE 1 INITIATION OF SECOND ORAL AMYLIN CANDIDATE ACCG-3535 EXPECTED IN Q4 2026 ALENIGLIPRON, AMYLIN AND COMBINATION DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION (ADA) 86TH SCIENTIFIC SESSIONS IN JUNE 2026 CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $1.5 BILLION AS OF MARCH 31, 2026, EXPECTED TO PROVIDE CASH RUNWAY THROUGH THE END OF 2028 SAN FRANCISCO, MAY 07, 2026 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINICAL-STAGE GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL ORAL SMALL MOLECULE THERAPEUTICS FOR METABOLIC DISEASES, WITH A FOCUS ON OBESITY, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE. WITH POSITIVE END OF PHASE 2 FEEDBACK RECEIVED FROM THE FDA FOR ALENIGLIPRON, WE ARE WELL POSITIONED TO START OUR PHASE 3 REGISTRATIONAL PROGRAM FOR CHRONIC WEIGHT MANAGEMENT IN THE THIRD QUARTER, SAID RAYMOND STEVENS, PH.D.

STRUCTURE THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

SAN FRANCISCO, APRIL 27, 2026 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINICAL-STAGE GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL ORAL SMALL MOLECULE THERAPEUTICS FOR METABOLIC DISEASES, WITH A FOCUS ON OBESITY, TODAY ANNOUNCED MULTIPLE PRESENTATIONS AT THE AMERICAN DIABETES ASSOCIATION (ADA) 86TH SCIENTIFIC SESSIONS, TAKING PLACE JUNE 58, 2026 IN NEW ORLEANS, LOUISIANA. THE PRESENTATIONS INCLUDE AN ORAL PRESENTATION ON THE ACCESS PHASE 2B CLINICAL TRIAL OF ALENIGLIPRON.

STRUCTURE THERAPEUTICS TO PRESENT ALENIGLIPRON, AMYLIN AND COMBINATION DATA AT THE AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

SAN FRANCISCO, APRIL 14, 2026 (GLOBE NEWSWIRE) -- STRUCTURE THERAPEUTICS INC. (NASDAQ: GPCR), A CLINICAL-STAGE GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL ORAL SMALL MOLECULE THERAPEUTICS FOR METABOLIC DISEASES, WITH A FOCUS ON OBESITY, TODAY ANNOUNCED THE APPOINTMENT OF MATTHEW LANG, J.D. AS CHIEF OPERATING OFFICER AND GENERAL COUNSEL. MR. LANG JOINS STRUCTURE THERAPEUTICS WITH MORE THAN FIFTEEN YEARS OF EXECUTIVE LEADERSHIP EXPERIENCE ACROSS GLOBAL BIOPHARMACEUTICAL ORGANIZATIONS, WITH DEEP EXPERTISE SPANNING LEGAL, CORPORATE STRATEGY, COMPLIANCE, RISK MANAGEMENT, AND BUSINESS DEVELOPMENT.

STRUCTURE THERAPEUTICS APPOINTS MATTHEW LANG, J.D. AS CHIEF OPERATING OFFICER AND GENERAL COUNSEL

PLACEBO-ADJUSTED MEAN WEIGHT LOSS OF 16.3% (39 LBS) AT 180 MG AND 16.0% (37 LBS) AT 240 MG AT 44 WEEKS WITH NO EVIDENCE OF WEIGHT LOSS PLATEAU IN ACCESS II, DEMONSTRATING HIGHEST EFFICACY AMONG ORAL GLP-1RAS AND COMPARABLE EFFICACY TO INJECTABLE GLP1-RAS

STRUCTURE THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM PHASE 2 ACCESS II TRIAL WITH ONCE-DAILY ORAL SMALL MOLECULE GLP-1 RECEPTOR AGONIST, ALENIGLIPRON

POSITIVE RESULTS FROM THE ALENIGLIPRON PHASE 2 ACCESS PROGRAMS IN DECEMBER 2025 DEMONSTRATED SIGNIFICANT WEIGHT LOSS ACROSS ALL DOSES AND UP TO 15.3% AT 36 WEEKS

STRUCTURE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

TOKYO, JAPAN AND CAMBRIDGE, UK, 12 JANUARY 2026  NXERA PHARMA CO., LTD. (NXERA OR THE COMPANY; TSE 4565) ANNOUNCED THAT IT HAS ENTERED INTO A LICENSE AGREEMENT (THE AGREEMENT) WITH A NEWLY ESTABLISHED INDEPENDENT COMPANY (THE NEWCO), CREATED BY A LEADING INTERNATIONAL LIFE SCIENCES INVESTMENT FIRM, TO ADVANCE NXERA'S G PROTEIN-COUPLED RECEPTOR (GPCR)-TARGETED PROGRAM (THE PROGRAM).

Structure Therapeutics Inc.

GPCR

Price

Financial Reports

No items found.

Press Releases

Structure Therapeutics Inc.

GPCR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GPCR